JP2012506442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506442A5 JP2012506442A5 JP2011533273A JP2011533273A JP2012506442A5 JP 2012506442 A5 JP2012506442 A5 JP 2012506442A5 JP 2011533273 A JP2011533273 A JP 2011533273A JP 2011533273 A JP2011533273 A JP 2011533273A JP 2012506442 A5 JP2012506442 A5 JP 2012506442A5
- Authority
- JP
- Japan
- Prior art keywords
- scar
- adhesion
- existing
- use according
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 231100000241 scar Toxicity 0.000 claims 39
- 210000001519 tissue Anatomy 0.000 claims 24
- 206010000050 Abdominal adhesions Diseases 0.000 claims 10
- 206010034238 Pelvic adhesions Diseases 0.000 claims 6
- 239000000090 biomarker Substances 0.000 claims 5
- 230000000747 cardiac effect Effects 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 230000035876 healing Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims 2
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 2
- 229940096397 interleukin-8 Drugs 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000011477 surgical intervention Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 102000012422 Collagen Type I Human genes 0.000 claims 1
- 108010022452 Collagen Type I Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 102000003898 interleukin-24 Human genes 0.000 claims 1
- 108090000237 interleukin-24 Proteins 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 4
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10683408P | 2008-10-20 | 2008-10-20 | |
| US61/106,834 | 2008-10-20 | ||
| PCT/US2009/061345 WO2010065206A1 (en) | 2008-10-20 | 2009-10-20 | Polypeptide for treating or preventing adhesions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506442A JP2012506442A (ja) | 2012-03-15 |
| JP2012506442A5 true JP2012506442A5 (cg-RX-API-DMAC7.html) | 2012-12-06 |
| JP5785085B2 JP5785085B2 (ja) | 2015-09-24 |
Family
ID=42108870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533273A Expired - Fee Related JP5785085B2 (ja) | 2008-10-20 | 2009-10-20 | 癒着を処置又は防止するためのポリペプチド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9034815B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2349310B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5785085B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101884616B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102256613B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009322865B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0919759A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2741302C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2349310T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2507496T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010065206A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2155228T3 (da) * | 2007-01-10 | 2014-07-07 | Purdue Research Foundation | Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor |
| WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| ES2685505T3 (es) | 2008-12-10 | 2018-10-09 | Purdue Research Foundation | Inhibidor de cinasas basado en péptidos de permeación celular |
| US9890195B2 (en) | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| US20110288036A1 (en) * | 2010-05-24 | 2011-11-24 | Cynthia Lander | Methods for Treating or Preventing Vascular Graft Failure |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| US9642888B2 (en) * | 2011-04-12 | 2017-05-09 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
| BR112014023068B1 (pt) * | 2012-03-23 | 2022-03-03 | Amicrobe, Inc | Composição aquosa para prevenir, inibir ou tratar infecção e respectivo uso |
| US20140072613A1 (en) * | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
| WO2016061145A1 (en) * | 2014-10-13 | 2016-04-21 | Symic Biomedical, Inc. | Synthetic proteoglycans for preventing tissue adhesion |
| SG11201703939XA (en) * | 2014-11-17 | 2017-06-29 | Moerae Matrix Inc | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| HK1246807A1 (zh) * | 2015-01-08 | 2018-09-14 | Moerae Matrix, Inc. | Mk2抑制剂肽的制剂 |
| CN107921082A (zh) | 2015-03-12 | 2018-04-17 | 莫伊莱麦屈克斯公司 | 含有mk2抑制剂肽的组合物用于治疗非小细胞肺癌的用途 |
| CN110740744A (zh) | 2017-04-06 | 2020-01-31 | 艾麦克罗比公司 | 性能和安全性增强的局部施用的抗微生物剂的组合物和应用 |
| RU2741247C1 (ru) * | 2020-10-13 | 2021-01-22 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) | Способ профилактики перитонеальных спаек женского таза |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) * | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) * | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) * | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| FR2550452B1 (fr) * | 1982-10-08 | 1992-05-22 | Glaxo Group Ltd | Dispositif pour administrer des medicaments a des patients |
| US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| FI88112C (fi) * | 1985-07-30 | 1993-04-13 | Glaxo Group Ltd | Anordning foer administrering av laekemedel till patienter |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| AU4115693A (en) | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| ES2149962T3 (es) * | 1993-12-09 | 2000-11-16 | Univ Jefferson | Compuestos y metodos para mutaciones dirigidas al sitio en celulas eucarioticas. |
| AU2003260668A1 (en) * | 2002-04-01 | 2003-10-20 | Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Biological affinity based delivery systems |
| EP1824336A4 (en) * | 2004-12-02 | 2009-10-14 | Univ North Carolina | INHIBITION OF PHOSPHORYLATION HSP27 TO TREAT VESICATION DISORDERS |
| CN101232895B (zh) * | 2005-04-15 | 2014-06-04 | 亚利桑那癌症治疗公司 | 用于治疗转移性癌症的治疗肽 |
| US20080293640A1 (en) * | 2007-01-10 | 2008-11-27 | Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of | Polypeptide inhibitors of HSP27 kinase and uses therefor |
| DK2155228T3 (da) * | 2007-01-10 | 2014-07-07 | Purdue Research Foundation | Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor |
| WO2008109794A2 (en) * | 2007-03-08 | 2008-09-12 | Tufts Medical Center | The role of the mk2 pathway in treating fibrosis and scarring |
| WO2009021137A2 (en) * | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| US20090269406A1 (en) * | 2008-04-02 | 2009-10-29 | Alyssa Panitch | Therapeutic uses of biocompatible biogel compositions |
-
2009
- 2009-10-20 CN CN200980148561.3A patent/CN102256613B/zh not_active Expired - Fee Related
- 2009-10-20 ES ES09830789.5T patent/ES2507496T3/es active Active
- 2009-10-20 US US12/582,516 patent/US9034815B2/en not_active Expired - Fee Related
- 2009-10-20 AU AU2009322865A patent/AU2009322865B2/en not_active Ceased
- 2009-10-20 EP EP09830789.5A patent/EP2349310B1/en not_active Not-in-force
- 2009-10-20 KR KR1020117011373A patent/KR101884616B1/ko not_active Expired - Fee Related
- 2009-10-20 CA CA2741302A patent/CA2741302C/en not_active Expired - Fee Related
- 2009-10-20 BR BRPI0919759A patent/BRPI0919759A2/pt not_active Application Discontinuation
- 2009-10-20 KR KR1020167036610A patent/KR20170001756A/ko not_active Ceased
- 2009-10-20 DK DK09830789.5T patent/DK2349310T3/da active
- 2009-10-20 JP JP2011533273A patent/JP5785085B2/ja not_active Expired - Fee Related
- 2009-10-20 WO PCT/US2009/061345 patent/WO2010065206A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506442A5 (cg-RX-API-DMAC7.html) | ||
| US6506731B1 (en) | Elastin peptide analogs and methods of using same | |
| US7786084B2 (en) | Treatment of burns | |
| JP5384342B2 (ja) | 癌のような変更された細胞遊走に関連する障害の治療のための薬理学的活性を有するペプチド | |
| AU2007342674B2 (en) | Polypeptide inhibitors of HSP27 kinase and uses therefor | |
| US7803757B2 (en) | Peptides based on the sequence of human lactoferrin and their use | |
| EP2402369A2 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
| JP2019104768A (ja) | 代謝性症候群を予防し又は治療するための方法 | |
| EA035733B1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
| JP2020196762A (ja) | 熱傷及び二次性合併症の予防及び治療方法 | |
| JP2011518179A5 (cg-RX-API-DMAC7.html) | ||
| JP2019533722A5 (cg-RX-API-DMAC7.html) | ||
| US6794362B1 (en) | Asparagine containing elastin peptide analogs | |
| RU2699712C1 (ru) | Антимикробный пептид и его применение | |
| RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2006506942A5 (cg-RX-API-DMAC7.html) | ||
| JP2020507623A5 (cg-RX-API-DMAC7.html) | ||
| WO2017101144A1 (zh) | 脂肪组织靶向多肽及其制备方法和应用 | |
| CN108530527B (zh) | 一种多肽oa-gl21及其提纯方法与应用 | |
| JP2003528885A (ja) | インシュリン強化ペプチド | |
| JP6548126B2 (ja) | Ｉｉｉ型コラーゲン産生促進剤 | |
| EP1392346A2 (en) | Composition and method for enhancing elasticity of tissue | |
| JP2016520592A (ja) | マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド | |
| JP2019038772A5 (cg-RX-API-DMAC7.html) | ||
| RU2010128602A (ru) | Циклический белок, не содержащий остатков цистеина |